Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

21. Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial)

Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial) Infectious complications and anastomotic leakage affect approximately 30 per cent of patients after colorectal cancer surgery. The aim of this multicentre randomized trial was to investigate whether selective decontamination of the digestive tract (SDD) reduces these complications of elective colorectal cancer surgery.The effectiveness of SDD was evaluated (...) in a multicentre, open-label RCT in six centres in the Netherlands. Patients with colorectal cancer scheduled for elective curative surgery with a primary anastomosis were eligible. Oral colistin, tobramycin and amphotericin B were administered to patients in the SDD group to decontaminate the digestive tract. Both treatment and control group received intravenous cefazolin and metronidazole for perioperative prophylaxis. Mechanical bowel preparation was given for left-sided colectomies, sigmoid and anterior

2019 EvidenceUpdates

22. Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests

Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests The impact of fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening on disease incidence and mortality is affected by participation, which might be influenced by ease of use of the FIT. We compared the participation rates and ease of use of 2 different FITs in a CRC screening program.There were two study designs within the Dutch CRC screening program. In a paired cohort

2019 EvidenceUpdates

23. Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline (Full text)

Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline | Journal of Global Oncology Search in: Menu Article Tools SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JGO.18.00214 Journal of Global Oncology - published online before print February 25, 2019 PMID: Treatment of Patients With Early-Stage (...) Colorectal Cancer: ASCO Resource-Stratified Guideline , MD, MPH 1 x Ainhoa Costas-Chavarri ; , MD 2 3 x Govind Nandakumar ; , MSPH 4 x Sarah Temin ; , MD, MBA 5 x Gilberto Lopes ; , MD, PhD 6 x Andres Cervantes ; , MD, PhD 7 8 x Marcia Cruz Correa ; , MD 9 x Rena Engineer ; , MD, PhD 10 x Chisato Hamashima ; , MD 11 x Gwo Fuang Ho ; , MD 12 x Fidel David Huitzil ; , MD 13 x Mona Malekzadeh Moghani ; , MD 14 x Ala I. Sharara ; , PhD 15 x Mariana C. Stern ; , MD 16 x Catherine Teh ; , MD 12 x Sara E

2019 American Society of Clinical Oncology Guidelines PubMed

24. Early Detection for Colorectal Cancer Resource-Stratified Guideline (Full text)

Early Detection for Colorectal Cancer Resource-Stratified Guideline Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline | Journal of Global Oncology Search in: Menu Article Tools SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JGO.18.00213 Journal of Global Oncology - published online before print February 25, 2019 PMID: Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline , MD, MBA 1 (...) Yantiss ; and , MD, PhD 16 x Marcia Cruz Correa 1 University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL 2 Keck School of Medicine of University of Southern California, Los Angeles, CA 3 American Society of Clinical Oncology, Alexandria, VA 4 American University of Beirut, Beirut, Lebanon 5 Hospital Clinico Universitario, Valencia, Spain 6 Rwanda Military Hospital, Kigali, Rwanda 7 Tata Memorial Centre, Mumbai, India 8 National Cancer Center, Tokyo, Japan 9 University of Malaya, Kuala

2019 American Society of Clinical Oncology Guidelines PubMed

25. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including

2019 Kaiser Permanente National Guideline Program

26. Clinical Utility Card - Heritable mutations which increase risk in colorectal and endometrial cancer

Clinical Utility Card - Heritable mutations which increase risk in colorectal and endometrial cancer 1 Public Summary Document Application No. 1504 - Heritable mutations which increase risk in colorectal and endometrial cancer Applicant: The Royal College of Pathologists of Australasia (RCPA) Date of MSAC consideration: MSAC 73 rd Meeting, 26-27 July 2018 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application (...) An application requesting Medicare Benefits Schedule (MBS) listing for genetic testing to identify inheritable mutations predisposing to colorectal and endometrial cancer, specifically the identification of heritable mutations associated with the clinical presentations of Lynch Syndrome (LS), Familial Adenomatous Polyposis (FAP), MUTYH-Associated Polyposis (MAP), Juvenile Polyposis Syndrome (JPS), Peutz-Jeghers Syndrome (PJS), and Hereditary Mixed Polyposis Syndrome (HMPS), was received from the RCPA

2019 Medical Services Advisory Committee

27. A cost-effectiveness analysis of a colorectal cancer screening program in safety net clinics

A cost-effectiveness analysis of a colorectal cancer screening program in safety net clinics STOP CRC is a cluster-randomized pragmatic study of a colorectal cancer (CRC) screening program within eight federally-qualified health centers (FQHCs) in Oregon and California promoting fecal immunochemical testing (FIT) with appropriate colonoscopy follow-up. Results are presented of a cost-effectiveness analysis of STOP CRC. Organization staff completed activity-based costing spreadsheets, assigning

2019 EvidenceUpdates

28. Robotic Versus Conventional Laparoscopic Surgery for Colorectal Cancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis

Robotic Versus Conventional Laparoscopic Surgery for Colorectal Cancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis Minimally invasive surgery has been considered as an alternative to open surgery by surgeons for colorectal cancer. However, the efficacy and safety profiles of robotic and conventional laparoscopic surgery for colorectal cancer remain unclear in the literature. The primary aim of this review was to determine whether robotic-assisted laparoscopic surgery (...) (RAS) has better clinical outcomes for colorectal cancer patients than conventional laparoscopic surgery (CLS).All randomized clinical trials (RCTs) and observational studies were systematically searched in the databases of CENTRAL, EMBASE and PubMed from their inception until January 2018. Case reports, case series and non-systematic reviews were excluded.Seventy-three studies (6 RCTs and 67 observational studies) were eligible (n = 169,236) for inclusion in the data synthesis. In comparison

2019 EvidenceUpdates

29. Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps: A Systematic Review and Meta-analysis. (PubMed)

Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps: A Systematic Review and Meta-analysis. Studies report inconsistent performance of fecal immunochemical tests (FITs) for colorectal cancer (CRC) and advanced adenomas.To summarize performance characteristics of FITs for CRC and advanced adenomas in average-risk persons undergoing screening colonoscopy (reference standard) and to identify factors affecting these characteristics.Ovid

2019 Annals of Internal Medicine

30. Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain

Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain The aim of the study was to measure the effect of three cost-neutral behavioral interventions on participation compared to the standard invitation letter in a population-based colorectal cancer screening program in 2014. For that purpose, a four-arm randomized field trial was conducted among 5077 individuals aged 50 to 69 years. Over an 8-week period, each

2019 EvidenceUpdates

31. Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110)

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110) The XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectal cancer. We tested the noninferiority of initial treatment with a fluoropyrimidine plus bevacizumab, followed by the addition of irinotecan at first progression (arm A) versus upfront use of fluoropyrimidine

2019 EvidenceUpdates

32. Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer

Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer SHTG Advice Statement | 1 Advice Statement 014-18 November 2018 Advice Statement Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer Advice for NHSScotland Colon capsule endoscopy (CCE-2 (...) ) is not recommended for routine use in NHSScotland for the detection of colorectal polyps and cancer. The clinical effectiveness evidence is currently limited, no relevant published evidence on the cost effectiveness of the technology was identified, and its place in the patient care pathway has still to be established. CCE-2 may however be considered as an additional testing option in patients who are able to undergo the intensive bowel cleansing needed for CCE-2 and who have contraindications for optical

2019 Evidence Notes from Healthcare Improvement Scotland

33. Association of oral anthraquinone laxatives and colorectal cancer and melanosis coli: protocol for a systematic review and meta-analysis

Association of oral anthraquinone laxatives and colorectal cancer and melanosis coli: protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

34. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and colorectal cancer risk: a meta-analysis

TP53 and MDM2 gene polymorphisms, gene-gene interaction, and colorectal cancer risk: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

35. The efficacy and safety of first-line systemic treatments among advanced colorectal cancer patients: a network meta-analysis of clinical trials

The efficacy and safety of first-line systemic treatments among advanced colorectal cancer patients: a network meta-analysis of clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

36. The effect of exercise-based interventions on health-related quality of life, physical and functional capacity, and side effects in older patients with colorectal cancer receiving medical antineoplastic treatments

The effect of exercise-based interventions on health-related quality of life, physical and functional capacity, and side effects in older patients with colorectal cancer receiving medical antineoplastic treatments Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD

2019 PROSPERO

37. Tumor-specific circulating cell-free DNA (ctDNA) and its clinical utility in predicting response to treatment or survival in patients with metastatic colorectal cancer: a systematic review

Tumor-specific circulating cell-free DNA (ctDNA) and its clinical utility in predicting response to treatment or survival in patients with metastatic colorectal cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

38. Risk factors, prevalence and risk of colorectal cancer among patients with young onset colonic adenomas

Risk factors, prevalence and risk of colorectal cancer among patients with young onset colonic adenomas Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

39. Association between constipation duration and the risk of colorectal cancer: systematic review and meta-analysis

Association between constipation duration and the risk of colorectal cancer: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

40. Qualitative experiences of colorectal cancer survivors: a systematic review

Qualitative experiences of colorectal cancer survivors: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO